BZT 2312
Alternative Names: BZE-2203; BZT-2312; Fast CAR T cellsLatest Information Update: 18 Sep 2025
At a glance
- Originator Shanghai Cell Therapy Group
- Class Antibodies; Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Solid tumours
Most Recent Events
- 30 May 2025 Adverse events, efficacy and pharmacokinetics data from a phase-0 trial in Solid tumours presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 25 Apr 2025 Efficacy and adverse event data from an early phase I investigator initiation trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Apr 2025 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)